Biotech Co.* |
Pharma Co. |
Type/Product Area | Terms/Details (Date) |
Aegerion |
Pfizer Inc. |
They entered cross- licensing deals covering patents related to microsomal triglyceride transfer protein inhibitors |
The University of Pennsylvania also was a party to the deal; terms were not disclosed (10/6) |
Affymetrix |
Wyeth |
Deal under which Wyeth extended its access to Affymetrix's GeneChip microarray technology |
The deal begun in 1994 was extended a further three years; Wyeth is using the technology in drug discovery and development; terms were not disclosed (10/24) |
Alantos |
Servier (France) |
Deal to develop Alantos' ALS 2-0426, an oral inhibitor of DPP-IV, for Type II diabetes; it is in Phase I trials |
Servier got rights outside the U.S.; Alantos is eligible to receive upfront and milestone payments of $75M, plus double-digit royalties on resulting sales; Servier also will pay for development through Phase II trials (10/24) |
AlphaRx Inc. |
Undisclosed U.S.-based company |
AlphaRx will do formulation work on three products from the partner, two of which are on the market |
The goal is to improve the products' effectiveness; the partner has a six-month option to license the products; AlphaRx gets an up-front payment, as well as potential milestone and royalty payments (11/7) |
Ambrilia |
Merck & Co. Inc. |
Merck got worldwide rights to Ambrilia's HIV/AIDS protease inhibitor program, including the Phase I product PPL-100 |
Ambrilia gets $17M up front and is eligible to receive up to $215M more in milestone payments; it also would get royalties on resulting sales (10/12) |
Arena |
Ortho-McNeil Pharmaceutical Inc. (unit of Johnson & Johnson) |
Ortho exercised its option to extend the research term in deal to develop drugs targeting the glucose- ependent insulinotropic receptor |
Arena is entitled to $2.4M in research funding under the one-year extension; the lead candidate targeting Type II diabetes is in Phase I trials (9/27) |
Asklepios Bio- |
GlaxoSmithKline plc (UK) |
Asklepios got certain rights to recombinant adeno- associated virus vector serotypes under a cross-licensing deal |
Asklepios' rights include three orphan indications; neither the technology licensed to GSK nor the monetary terms was disclosed (9/28) |
Biogen Idec |
UCB SA (Belgium) |
Deal to to develop and market UCB's Phase I product CDP323 for multiple sclerosis and other potential indications |
UCB gets up-front and milestone payments that could exceed $200M; Biogen also will help fund development; commercialization costs and profits would be shared equally (10/2) |
BioSante |
Bradley Pharmaceuticals Inc. |
Bradley got U.S rights to Bio-E-Gel (transdermal estradiol gel), which is under FDA review for treating hot flashes |
BioSante gets $2.625M and Antares $0.875M up front; milestones could push payments to BioSante to more than $40M, and to more than $13M for Antares; they also would get royalties on resulting sales (11/8) |
Biotica |
Wyeth Pharmaceuticals |
Exclusive deal to develop rapamycin analogues from Biotica that target diseases in multiple therapeutic areas |
Biotica gets up-front, research and milestone payments that could reach $195M if multiple products are developed; it also would get royalties on resulting sales (10/5) |
Biovitrum AB |
Orchid Chemicals & Pharmaceuticals Ltd. (India) |
Deal under which Orchid will provide medicinal chemistry services for Biovitrum |
The six-month deal covers certain Biovitrum compounds; the deal could be extended and expanded; terms were not disclosed (10/30) |
BrainCells |
NV Organon (the Netherlands; unit of Akzo Nobel) |
Deal to identify neuroscience applications for compounds formerly in the Organon clinical-stage pipeline |
BrainCells will use its neurogenesis technology in the repositioning effort; terms of the deal were not disclosed (10/23) |
Can-Fite |
Seikagaku Corp. (Japan) |
Seikagaku got rights to CF101 in Japan for use in inflammatory indications; the deal does not include ophthalmic indications |
Can-Fite gets $3.5M up front, and up to $16M more in milestone payments; it also would get royalties on sales (9/25) |
Caprion |
Centocor Inc. (unit of Johnson & Johnson) |
Centocor got exclusive rights to a number of protein targets that may have applicability in cancer indications |
Caprion is entitled to an up-front payment and license fees, along with potential milestone payments and royalties on any resulting sales (10/11) |
Cellzome Inc.* |
Novartis AG |
They extended deal focused on molecular pathways through June 2008; it began in 2004 |
Cellzome technology is being used to identify targets for several disease areas, and to gauge the effects of Novartis compounds; terms of the deal were not disclosed (10/25) |
Cenix |
Merck KGaA (Germany) |
Deal under which Cenix will provide RNAi-based services to assist Merck with target discovery and validation |
The deal focuses on oncology, and includes an option to expand to other disease programs; terms were not disclosed (9/27) |
Cerexa Inc.* |
Meiji Seika Kaisha Ltd. (Japan) |
Cerexa got exclusive rights to ME1036, a broad- pectrum antibiotic agent |
Initiation of Phase I trials was expected in the first half of 2007; terms of the deal were not disclosed (11/1) |
ChemBridge |
AstraZeneca plc (UK) |
Deal to develop small- molecule libraries for use in drug discovery at AstraZeneca |
The multiyear deal also includes ChemBridge Corp.; terms and further details were not disclosed (9/21) |
Debiopharm |
Cambridge Antibody Technology (unit of AstraZeneca plc; UK) |
Exclusive deal to develop and market Debiopharm's SC-1 and derivative products; it is a fully human monoclonal IgM antibody |
The Phase I/II product targets gastric carcinoma cells; Debiopharm is entitled to upfront and milestone payments in the deal, as well as royalties on resulting sales (10/16) |
D-Pharm Ltd.* |
Yungjin Pharmaceutical Co. Ltd. (South Korea) |
Yungjin got rights in Korea to the stroke product candidate DP-b99 |
D-Pharm gets $1M up front, along with potential milestone payments; it also will supply product in exchange for a percentage of the reimbursement price (10/23) |
EKR |
Helsinn Healthcare SA (Switzerland) |
EKR acquired North American rights to the approved oral gel product Gelclair |
The product is used in cancer-related pain associated with oral mucositis/stomatitis; terms of the deal were not disclosed (10/12) |
Eurand |
GlaxoSmithKline plc(UK) |
Eurand will use its taste- masking and tablet-disintegration technologies to develop a new formulation of an undisclosed GSK product |
GSK will fund the work, and Eurand would get royalties on resulting sales; Eurand also has certain commercialization rights to the product outside the U.S. (10/4) |
Galapagos NV |
LEO Pharma A/S (Denmark) |
Galapagos will use part of its natural compound library for high-throughput screening of LEO antibacterial compounds |
Galapagos gets up to €0.4M in project fees and up to €3M in milestone payments; it also would get royalties on resulting sales (11/1) |
GeneGo Inc.* |
Merck KGaA (Germany) |
Pfizer gained expanded access to the MetaCore systems biology platform |
The deal now allows all Merck employees access to the technology in perpetuity; terms were not disclosed (9/26) |
Gene Logic |
Eli Lilly and Co. |
Deal to seek alternative development paths for multiple Lilly drug candidates and an option to license compounds Lilly |
The compounds were discontinued for reasons other than safety; Gene Logic is entitled to milestone and royalty payments, does not develop (10/12) |
GenOdyssee |
Baxter International Inc. |
GenOdyssee will use its protein and other other technologies in a deal to discover novel blood- clotting factors |
Baxter will develop and bring to market any resulting products; terms of the deal were not disclosed (10/23) |
GTC |
LFB Biotechnologies (subsidiary of LFB SA; France) |
Deal to develop recombinant plasma proteins and monoclonal antibodies using GTC's transgenic production platform |
GTC has rights in North America, and LFB in Europe; rights elsewhere are shared, as will be costs and profits; LFB bought about $6M in GTC stock as part of a $25M equity commitment, which would give it a 19.9% stake in GTC (10/2) |
ImmunoGen |
Sanofi-Aventis Group (France) resulting sales (10/18) |
Sanofi got nonexclusive rights to use ImmunoGen's resurfacing technology to humanize antibodies in all indications |
Sanofi previously had rights only in cancer applications under a 2003 deal; ImmunoGen gets a $1M license fee, plus milestone payments up to $4.5M, and royalties on any |
Indevus Pharmaceuticals |
Madaus GmbH (Germany) |
Madaus got rights to the overactive bladder product Sanctura SR outside the U.S. except in Canada, Japan, Korea and China |
Rights will be shared in the four ex-U.S. countries not covered in the license agreement; Indevus will get royalties and manufacturing fees on sales in Madaus' territories (11/6) |
Inovio |
Wyeth |
Wyeth got nonexclusive rights to use electroporation-based delivery technology with certain therapeutic DNA vaccines |
Inovio gets a $4.5M license fee, annual maintenance fees, research support, and up to $60M in clinical and regulatory milestones; it also would supply the devices, and get royalties on resulting sales (11/7) |
Inspire |
FAES Farma SA (Spain) |
Inspire got U.S. and Canadian rights to bilastine, a Phase III oral antihistamine compound for treating allergic rhinitis |
Inspire also got rights to an ocular formulation of the compound in various markets worldwide; FAES gets $7M up front, and up to $82M in milestone payments, as well as royalties of 14% to 16% on resulting sales of the oral product (11/1) |
IntegraGen |
Royal DSM NV (the Netherlands) |
Collaboration to develop molecular diagnostic products for personalized health care |
IntegraGen gets up-front and license fees, R&D funding and royalties on resulting sales; separately, DSM Venturing invested €2M in IntegraGen (11/6) |
Intercell AG |
Merck & Co. Inc. |
They extended relationship to include development of a prophylactic vaccine against Group A Streptococcus infections |
Intercell will provide Merck antigens that have shown preclinical promise; Intercell gets $9.5M up front, and is eligible to receive milestone payments of up to $76M, as well as royalties on resulting sales (10/26) |
InterMune |
F. Hoffmann- La Roche Ltd. (Switzerland) |
Exclusive deal to develop and market products from InterMune's hepatitis C virus protease inhibitor program; they also will work on second- generation compounds |
The deal includes lead product ITMN-191, which is nearing Phase I trials; InterMune gets $60M up front and up to $470M in milestones related to ITMN-191; Roche will fund 67% of development costs and would pay royalties on sales; InterMune has a 50-50 commercialization option in the U.S. (10/16) |
Isogenica |
UCB SA |
Deal to discover novel peptide ligands, which UCB would incorporate into therapeutic products |
The focus of the research and license deal is antibiotics; terms of the deal were not disclosed (11/6) |
Jennerex |
Green Cross Corp. (South Korea) |
Green Cross got rights in Korea to JX-594, an oncolytic vaccinia virus |
Liver cancer is the initial indication; Green Cross will fund Korean development, and would pay royalties on any resulting sales (10/17) |
Keryx Bio- |
Kyowa Hakko Kogyo Co. Ltd. (Japan) |
Keryx got rights outside Japan to UCN-01, a multi-kinase inhibitor in Phase II trials in cancer indications |
Kyowa Hakko is entitled to up-front, milestone and royalty payments in the deal (10/4) |
LibraGen* |
Sanofi-Aventis Group (France) |
Deal to use LibraGen's expertise in microbial biodiversity to discover compounds for treating infectious diseases and cancer |
They intend to discover new chemical structures derived from non-cultivable microorganisms; LibraGen is eligible to receive milestone and royalty payments (10/25) |
MediciNova |
Meiji Seika Kaisha Ltd. (Japan) |
MediciNova acquired two small- molecule antithrombic agents, MN-447 and MN-462 |
Rights to the preclinical products are worldwide outside Japan and certain other Asian countries; terms of the deal were not disclosed (11/1) |
MedImmune |
ZLB Behring (unit of CSL Ltd.; Australia) |
ZLB acquired the immuno- globulin product CytoGam, which is marketed for prevention of cytomegalovirus infection |
MedImmune gets $50M up front and up to $70M more in sales-based milestones (11/8) |
Melior |
Merck & Co. Inc. |
Melior will use its in vivo discovery platform to evaluate the activity of certain neuroscience compounds from Merck |
Melior gets undisclosed fees for granting Merck priority access to the technology; further terms were not disclosed (11/7) |
MSM Protein |
Cambridge Antibody Technology (unit of Astrazeneca plc; UK) |
Collaboration to discover antibody- based drugs targeting multi-spanning membrane proteins |
MSM will apply its technologies to antibody libraries from CAT, which will fund the work; both companies could have milestone and royalty obligations on resulting products (10/17) |
Nabi Bio- |
Fresenius Medical Care AG & Co. KGaA (Germany) |
Fresenius is acquiring Nabi's PhosLo (calcium acetate) product and related assets |
Nabi will get $65M at closing and up to $20M more in milestone payments, along with royalty payments on a new formulation in development that could push the deal's value to $150M (10/12) |
OncoMethylome |
Schering-Plough Corp. |
Schering-Plough got rights to use assay technology for measuring the methylation status of the MGMT gene |
The effort is focused on optimizing SP's Temodar therapy in patients with glioblastoma multiforme; OncoMethylome gets a license payment, sample-processing fees and potential milestone payments (10/24) |
Pharmacopeia |
Schering-Plough Corp. |
They extended until April 2007 a deal started in 2003 to develop small-molecule therapeutics |
Pharmacopeia gets funding for 10 chemistry employees, and remains entitled to milestone and royalty payments on resulting compounds (9/28) |
Plexxikon |
F. Hoffmann- La Roche Ltd. (Switzerland) |
Deal to develop and market PLX4032, Plexxikon's agent targeting a mutated form of the BRAF kinase gene; Phase I trials of the lead compound, PLX4032, are upcoming |
Plexxikon gets $40M up front and $6M in research funding over two years; it could receive $660M in development and sales milestones for multiple indications and/or compounds, as well as royalties on sales; it retained a U.S. co-promotion option (10/4) |
Plexxikon |
Servier (France) |
Deal to discover non-peptidic inhibitors of renin, which may be applicable in hypertension, renal failure and vascular disease |
Plexxikon gets an up-front payment, research funding and potential milestone payments that together could exceed $100M; Servier gets worldwide rights, and would pay royalties on resulting sales (10/2) |
ProStrakan |
Novartis AG (Switzerland) |
Collaboration to develop antibodies for treating bone-related diseases |
ProStrakan gets up-front and R&D payments of $5.75M over two years; it also could earn $140M in development and sales milestones; ProStrakan retained rights to small-molecule approaches (9/27) |
Protalix |
Teva Pharmaceutical Industries Ltd. (Israel) |
Teva got rights to two proteins, which will be developed using Protalix's plant cell culture platform |
Protalix is entitled to milestone and royalty payments in the deal; it also retained certain exclusive manufacturing rights (9/26) |
Quark |
Pfizer Inc. |
Pfizer got exclusive rights to the RTP- 01 gene, and to molecules that modify its expression or function |
RTP-801 is involved in the development of pathologic blood vessels, and is being studied in age-related macular degeneration; terms of the deal were not disclosed; Quark collaborator SR Pharma Ltd. said it was entitled to $2M up front and up to $95M in milestone payments in the deal, as well as royalties on sales (9/26) |
Regeneron |
Bayer HealthCare (Germany) |
Deal to develop and market Regeneron's VEGF Trap technology outside the U.S. for treating eye diseases |
Regeneron gets $75M up front and up to $110M in development milestones, as well as $135M in sales milestones; they will share ex-U.S. costs and any profits (10/18) |
Santarus Inc. |
Schering-Plough Corp. |
Schering-Plough got certain exclusive rights to Zegerid products for the over-the-counter market in the U.S. and Canada |
SP will develop and market the 20-mg (lower) dose of omeprazole for heartburn- related indications; Santarus gets $15M up front and up to $65M in regulatory and sales milestones, as well as royalties on sales (10/18) |
Sapphire |
Ono Pharmaceutical Co. Ltd. (Japan) |
Ono got rights in Japan, Korea and Taiwan to RC-1291, a small- molecule ghrelin mimetic |
Sapphire is entitled to up-front, milestone and royalty payments in the deal; RC-1291 is being developed for treating cancer anorexia/cachexia (10/26) |
Scolr Pharma Inc. (AMEX:DDD) |
Undisclosed U.S.- ased company |
Deal to develop an oral form of an antiviral compound being developed against influenza |
Scolr will use its CDT drug delivery technology in the effort; research could lead to a license agreement; terms of the deal were not disclosed (9/22) |
ThromboGenics |
Roche Diagnostics (Switzerland) |
Roche got rights to diagnostic applications of the pro-angiogenic placental growth factor PIGF in vascular disorders |
Terms of the worldwide, co-exclusive license agreement were not disclosed (10/19) |
TopoTarget |
LEO Pharma A/S (Denmark) |
LEO got worldwide rights to the preclinical HDAC inhibitor PXD118490 for treating psoriasis and other dermatological disorders |
TopoTarget and CuraGen get €2M up front and up to €32M in milestone payments, as well as royalties on any resulting sales; they will equally share any payments from LEO (11/2) |
Transition |
Elan Corp. plc (Ireland) |
Deal to develop and market Transition's Phase I product AZD- 03 for treatment of Alzheimer's disease |
Transition gets up-front payments of $15M, and is eligible to receive up to $185M in milestone payments; they will share costs and any profits, with Elan's share currently 70% (9/27) |
Warren |
Shire plc (UK) |
Shire got rights to tissue protective cytokine (TPC) technology in areas outside the central nervous system |
Warren has identified TPCs that are modifications of erythropoietin; terms of Shire's exclusive license were not disclosed (10/3) |
ViRexx |
Defiante Farmaceutica Lda and Tecnogen SCpA (units of Sigma-Tau; Italy) |
Deal for the manufacturing and distribution of ViRexx's cancer product Ovarex MAb in Europe and the Middle East |
Defiante will purchase C$2M ($1.8M) in ViRexx stock and up to to C$4.5M more; ViRexx stands to receive royalties of 25% on sales in Europe and the Middle East (11/6) |
Viropro Inc. |
Biochallenge SA (Tunisia) |
Biochallenge got rights to four biogeneric products that it would commercialize in Africa, the Middle East and certain other areas |
Viropro is eligible to receive $42M in licensing fees, development and technology transfer costs, and royalties on future sales; Viropro also got a 14% interest in the project (11/7) |
Xanthus |
Schering AG (Germany) |
Xanthus got exclusive rights to oral fludarabine in the U.S. |
Schering is entitled to up-front, milestone and royalty payments in the deal; the cancer drug is approved in Europe and Canada (10/3) |
Xenon |
Takeda Pharmaceutical Co. Ltd. (Japan) |
Takeda got rights in Japan and certain Asian countries to oral formulations of Xenon's preclinical pain drug XEN401 |
Xenon gets up-front and potential mile- stone payments of up to $75M, as well as royalties on resulting sales; it also gets a $5M equity investment; Takeda also has an option on backup compounds (10/2) |
XOMA Ltd. |
Takeda Pharmaceutical Co. Ltd. (Japan) |
Deal under which XOMA will discover therapeutic antibodies against multiple targets selected by Takeda |
XOMA is entitled to up-front, milestone and R&D payments that together could total $100M; it also would get royalties on any resulting sales (11/2) |
Ziopharm |
Baxter Healthcare Corp. | Ziopharm is acquiring the Phase I cancer agent indibulin (ZIO-301), which targets mitosis | The definitive agreement calls for Baxter to receive an up- front payment; it also is eligible to get milestone and royalty payments (11/6) |
| Notes: | |||
| # The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
| * Private companies are indicated with an asterisk. | |||
| Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
| AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; OSE = Osaka Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TEL = Tel Aviv Stock Exchange; TSX = Toronto Stock Exchange; VSE = Vienna Stock Exchange. | |||
To read more on related topics, click on one of the words below.